Down syndrome trial may hold key to learning

March 26, 2013
Down syndrome trial may hold key to learning
A world-first trial will use a common cough syrup ingredient to boost the quality of life of up to six million people with Down syndrome.

(Medical Xpress)—An ingredient used for decades in cough syrup, and to treat a variety of conditions, could hold the key to improving memory, language, and learning in people with Down syndrome.

In the first trial of its kind targeting cognitive impairment in people with , researchers at Monash University are currently investigating the effectiveness of the ingredient, known as BTD-001, and its potential to significantly improve the quality of life of people with Down syndrome - the most common genetic form of affecting six million people worldwide.

Principal Investigator, Director of the Centre for Health Victoria, Associate Professor Bob Davis, said early scientific evidence into the drug's ability to improve the cognitive function of people with Down syndrome was promising.

"Although it's too soon to draw any conclusions, we're hopeful this trial and the continued development of the drug could lead to a product that can improve the , and ultimately the quality of life of people with Down syndrome," Associate Professor Davis said.

"With further development, we hope this could provide a path to improving some of the difficulties those living with Down syndrome may have, such as the ability to learn at school, to become self reliant, to get a job or to manage their own finances.

"To date management has tended to focus on treating the physical complications of Down syndrome, but we now have a better understanding of the science underlying how Down syndrome impacts to cause ."

The clinical study is based on recent research at Stanford University which first uncovered the strong potential of BTD-001 to improve reasoning, memory and learning capabilities of people with Down syndrome.

Associate Professor Davis and his team are currently trialling a new lower dose formulation of the drug, which was discovered in the 1920s, and later used in , as well as a respiratory stimulant to treat a wide variety of conditions including dementia until the 1980s. The drug is still used in cough syrup for children in parts of the world.

Associate Professor Davis and researchers are working with people with Down syndrome aged between 13 and 35. They hope to recruit participants from Adelaide, Brisbane, Launceston, Melbourne, Perth, Sydney, and Woolongong to take part in the trial.

Development of this product is supported by the USA Government through the National Institute of Health and US based company Balance Therapeutics and its subsidiary based in Melbourne, Australia.

Related Stories

Scientist tests promising drug on those with Down syndrome

August 2, 2011

(PhysOrg.com) -- A University of Colorado School of Medicine scientist is finishing a major clinical trial on a drug that could boost cognitive function in those with Down syndrome, significantly improving their quality of ...

Fragile X study offers new drug hope

September 24, 2012

(Medical Xpress)—An experimental drug can improve sociability in patients with fragile X syndrome and may be helpful as a treatment for autism, according to a study.

Lithium restores cognitive function in Down syndrome mice

December 3, 2012

Down syndrome is a neurodevelopmental disorder that is the leading cause of genetically defined intellectual disability. In the brain, Down syndrome results in alterations in the connections between neurons and a reduction ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.